ES2187520T3 - Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina. - Google Patents

Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.

Info

Publication number
ES2187520T3
ES2187520T3 ES94910445T ES94910445T ES2187520T3 ES 2187520 T3 ES2187520 T3 ES 2187520T3 ES 94910445 T ES94910445 T ES 94910445T ES 94910445 T ES94910445 T ES 94910445T ES 2187520 T3 ES2187520 T3 ES 2187520T3
Authority
ES
Spain
Prior art keywords
pct
cytoquine
muramil
peptide
association
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910445T
Other languages
English (en)
Inventor
Louis Chedid
Georges Bahr
Pierre Lefrancier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr
Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr
Application filed by Vacsyn SA filed Critical Vacsyn SA
Application granted granted Critical
Publication of ES2187520T3 publication Critical patent/ES2187520T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION QUE ASOCIA, PARA SU APLICACION EN TERAPIA HUMANA, AL MENOS UNA CITOQUINA NATURAL O RECOMBINANTE, PREFERENTEMENTE HUMANA, CON LA MENOS UN MURAMILPEPTIDO ELEGIDO ENTRE LOS QUE, CUANDO SON ADMINISTRADOS "IN VIVO" EN ASOCIACION CON UN INTERFERON, INDUCEN TAMBIEN LA PRODUCCION INCREMENTADA IN VIVO DE UN ANTAGONISTA IL-1 RA DEL RECEPTOR DE LA INTERLEUQUINA I Y, PREFERENTEMENTE, NO INDUCEN UN CRECIMIENTO DE LAS CITOQUINAS IL-1, TNF Y IL-8. SE PUEDE UTILIZAR PARA TERAPIAS ANTIVIRALES, ANTITUMORALES Y/O PARA FAVORECER UNA RECONSTITUCION DEL SISTEMA HEMATOPOIETICO, PARTICULARMENTE EN PERSONAS CUYO SISTEMA INMUNITARIO ES O SE HA VUELTO DEFICIENTE.
ES94910445T 1993-03-19 1994-03-21 Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina. Expired - Lifetime ES2187520T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9303230A FR2702659B1 (fr) 1993-03-19 1993-03-19 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr) 1993-03-31 1993-03-31 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .

Publications (1)

Publication Number Publication Date
ES2187520T3 true ES2187520T3 (es) 2003-06-16

Family

ID=26230187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910445T Expired - Lifetime ES2187520T3 (es) 1993-03-19 1994-03-21 Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.

Country Status (11)

Country Link
US (1) US5932208A (es)
EP (1) EP0689449B1 (es)
JP (1) JP3723206B2 (es)
AT (1) ATE226828T1 (es)
AU (1) AU6285694A (es)
CA (1) CA2157758A1 (es)
DE (1) DE69431620T2 (es)
DK (1) DK0689449T3 (es)
ES (1) ES2187520T3 (es)
PT (1) PT689449E (es)
WO (1) WO1994021275A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6267968B1 (en) * 1995-04-07 2001-07-31 Vacsyn S.A. MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DZ3332A1 (fr) 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
FR2809106A1 (fr) * 2000-05-17 2001-11-23 Istac Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
DE60234782D1 (de) * 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
US20030097409A1 (en) * 2001-10-05 2003-05-22 Hungchou Tsai Systems and methods for securing computers
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7546638B2 (en) * 2003-03-18 2009-06-09 Symantec Corporation Automated identification and clean-up of malicious computer code
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CN101132776A (zh) * 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954B1 (en) 2018-08-13 2025-05-07 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
EP4411592B1 (de) 2023-02-06 2025-04-02 Sick Ag Verfahren zum lesen eines optischen codes und optoelektronischer codeleser

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) * 1986-08-13 1987-12-31 Takeda Chemical Industries Ltd Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination

Also Published As

Publication number Publication date
DK0689449T3 (da) 2003-03-03
JPH08511235A (ja) 1996-11-26
DE69431620D1 (de) 2002-12-05
CA2157758A1 (en) 1994-09-29
EP0689449B1 (fr) 2002-10-30
EP0689449A1 (fr) 1996-01-03
DE69431620T2 (de) 2003-07-03
US5932208A (en) 1999-08-03
PT689449E (pt) 2003-03-31
WO1994021275A1 (fr) 1994-09-29
ATE226828T1 (de) 2002-11-15
AU6285694A (en) 1994-10-11
JP3723206B2 (ja) 2005-12-07

Similar Documents

Publication Publication Date Title
PT689449E (pt) Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina
Stern et al. Interleukin-12 an integral cytokine in the immune response
CA1288694C (en) Process for treatment of diseases
Lacey et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1, 25 dihydroxyvitamin D3.
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
NO965621D0 (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
Lefort et al. IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells
AR034049A1 (es) Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de pacientes anemicos
Yeh et al. Changes in serum tumour necrosis factor-α in burned patients
Yoshikai et al. The role of interleukin 15 in mounting an immune response against microbial infections
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
DK0613499T3 (da) Humame IT-4-mutantproteiner
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
Morhenn The etiology of lichen planus: a hypothesis
CA2388338A1 (en) Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
ATE442387T1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
ATE159172T1 (de) Peptide und deren verwendung
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
DE69836278D1 (de) Allele formen von menschlichem stat3
Femandez‐Botran et al. Control of the production of soluble interleukin‐4 receptors: Implications in immunoregulation
DK0858345T3 (da) Anvendelse af muteiner af vildtypecytokiner som immunogener
Rouse Use of heat-pressed leucite reinforced porcelain in “difficult” veneer cases: A clinical report
Bajetto et al. IL-1 receptor antagonist production by B and T lymphocytes
Rubbert-Roth et al. Treatment of patients with rheumatoid arthritis with the interleukin-1 receptor antagonist anakinra (Kineret®)
Barak et al. The M20 IL-1 inhibitor is distinct from the IL-1ra